Manufacturers report phase 3 study results for Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution in adult patients with idiopathic hypersomnia

In a withdrawal study, those who continued on this lower-sodium formulation of sodium oxybate had fewer symptoms vs those switched to placebo (difference in Epworth Sleepiness Scale and Idiopathic Hypersomnia Severity Scale scores of -6.51 & -12.00 respectively, p<0001 for both).

Source:

Biospace Inc.